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Abstract
Brain-derived neurotrophic factor (BDNF) promotes survival and synaptic plasticity in the human brain. The Val66Met
polymorphism of the BDNF gene interferes with intracellular trafficking, packaging, and regulated secretion of this
neurotrophin. The human prefrontal cortex (PFC) shows lifelong neuroplastic adaption implicating the Val66Met BDNF
polymorphism in the recovery of higher-order executive functions after traumatic brain injury (TBI). In this study, we
examined the effect of this BDNF polymorphism on the preservation of general intelligence following TBI. We genotyped a
sample of male Vietnam combat veterans (n= 156) consisting of a frontal lobe lesion group with focal penetrating head
injuries for the Val66Met BDNF polymorphism. Val/Met did not differ from Val/Val genotypes in general cognitive ability
before TBI. However, we found substantial average differences between these groups in general intelligence (< half a
standard deviation or 8 IQ points), verbal comprehension (6 IQ points), perceptual organization (6 IQ points), working
memory (8 IQ points), and processing speed (8 IQ points) after TBI. These results support the conclusion that Val/Met
genotypes preserve general cognitive functioning, whereas Val/Val genotypes are largely susceptible to TBI.
Citation: Barbey AK, Colom R, Paul E, Forbes C, Krueger F, et al. (2014) Preservation of General Intelligence following Traumatic Brain Injury: Contributions of the
Met66 Brain-Derived Neurotrophic Factor. PLoS ONE 9(2): e88733. doi:10.1371/journal.pone.0088733
Editor: Renping Zhou, Rutgers University, United States of America
Received October 30, 2013; Accepted January 10, 2014; Published February 26, 2014
Copyright:  2014 Barbey et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by funding from the U.S. National Institute of Neurological Disorders and Stroke intramural research program and a project
grant from the United States Army Medical Research and Material Command administered by the Henry M. Jackson Foundation (Vietnam Head Injury Study Phase
III: a 30-year post-injury follow-up study, grant number DAMD17-01-1-0675). R. Colom was supported by grant PSI2010-20364 from Ministerio de Ciencia e
Innovacio´n [Ministry of Science and Innovation, Spain] and and CEMU-2012-004 [Universidad Autonoma de Madrid]. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: barbey@illinois.edu (AB); jgrafman@ric.edu (JG)
Introduction
Traumatic Brain Injury (TBI) is a global public health epidemic.
In the US alone, more than 3 million people sustain a TBI
annually. It is one of the most disabling injuries as it results in
motor and sensory deficits as well as severe cognitive, emotional,
and psychosocial impairment. Fueled by the recognition of TBI as
the ‘‘signature injury’’ in our wounded soldiers in Iraq and
Afghanistan and its often devastating impact on athletes playing
contact sports, interest in TBI has increased exponentially.
Unfortunately, despite increased awareness of its detrimental
consequences, there has been little progress in developing effective
TBI interventions. Following TBI, the brain attempts to activate
repair mechanisms and stimulate neuroregeneration, which may
be facilitated by the presence of a unique family of neurotrophic
factors, including nerve growth factor, glia-derived neurotrophic
factor, neurotrophin-3, and brain-derived neurotrophic factor
(BDNF). In this study, we build upon our prior work [1,2] by
investigating the relationship between variations in the BDNF
gene and preservation of general intelligence in the prefrontal
cortex (PFC) after TBI. Damage to the PFC leads to impairment
in executive function, which normally allows individuals to
effectively engage in complex goal-directed behaviors, whereas
the domains of perception and language are more often preserved
[3].
BDNF has emerged as a major regulator of synaptic connec-
tions [4], synaptic plasticity [5,6], and neural survival and growth
[7,8]. Within the BDNF gene, a distinct haplotype containing a
frequent single-nucleotide polymorphism (SNP), located at nucle-
otide 196 (dbSNP rs6265), produces a G-to-A substitution, which
results in a valine-to-methionine (Val66Met) substitution at codon
66 in the propeptide of the BDNF molecule [9,10]. This SNP
alters the intracellular tracking and packaging of pro-BDNF,
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affecting the regulated secretion and neuroplastic effect of mature
BDNF [11].
The Val66Met BDNF polymorphism has been linked to
cognitive functioning and clinical pathology [12]. In healthy
populations, the methionine (Met) allele has been linked to
impaired episodic memory, working memory, and hippocampal
function [11,13–16], although a recent study showed a functional
advantage for the Met allele when cognitive control, such as
response inhibition, is required [17]. Furthermore, the Met allele
has been associated with lower hippocampal levels of N-
acetylaspartate [11] and less gray matter volume throughout the
PFC and middle temporal lobes as well as limbic structures such as
the amygdala [16,18–20]. In clinical populations, the Met allele
has been associated with a wide range of neurodegenerative and
psychiatric disorders such as Alzheimer’s disease [21–23] and
bipolar disorder [24,25], arguing that a common clinical symptom
of these disorders is a varying degree of impairment in higher
cognitive abilities [26,27].
To our knowledge, the way in which the Val66Met BDNF
polymorphism affects the preservation of general intelligence after
TBI has not been systematically examined. Recent evidence
suggests that this approach can be productively applied to
understand recovery of executive function [1] and cognitive
performance following TBI [28], and motivates the present more
comprehensive investigation of general intelligence. A central aim
of the current effort is to investigate the way in which the
Val66Met BDNF polymorphism affects the preservation of specific
facets of human intelligence, advancing prior research by
administering a comprehensive assessment of general intelligence
and applying latent variable modeling to examine key facets of
intellectual ability (i.e., verbal comprehension, perceptual organi-
zation, working memory, and processing speed). Here, we
genotyped a sample of male Vietnam combat veterans with focal
penetrating TBI and administrated the Wechsler Adult Intelli-
gence Scale to examine specific competencies for general
intelligence. Importantly, veterans with different genotypes did
not show any difference in general intelligence before TBI.
Materials and Methods
Participant Data
Participants were drawn from the Phase 3 Vietnam Head Injury
Study (VHIS) registry, which includes American male veterans
who all suffered brain damage from penetrating head injuries in
the Vietnam War (n=171). This study was approved by the
National Naval Medical Center Institutional Review Board and, in
accordance with stated guidelines, all subjects read and signed
informed consent documents. Since our participants have had an
injury that may have impaired their ability to think clearly and
make decisions, we ask that they travel with a primary caregiver
and name them as a Durable Power of Attorney for research and
medical care at NNMC. Phase 3 testing occurred between April
2003 and November 2006.
Genotyping
156 participants were genotyped for the single-nucleotide
(G196A) polymorphism (SNP) of the BDNF gene that is located
on chromosome 11p13 [33]. The Val66Met polymorphism of the
BDNF gene (dbSNP identifier: rs6265; GenBank accession
number 2174122) is a G-to-A substitution, which results in
replacement of the Val at codon 66 of the BDNF protein by Met.
Individuals who are G/G homozygous produce only the Val-
containing isoform of the proBDNF protein, A/A homozygous
individuals produce only the Met-containing isoform of proBDNF,
and G/A heterozygous individuals produce both protein isoforms.
Note that groups with Met/Val and Met/Met genotypes were
combined for statistical analyses into a Met/2 BDNF group
(frontal lobe lesion group: Val/Val = 97, Val/Met = 56, Met/
Met = 3), since the frequency of the Met/Met genotype was low
and the Met/Met-containing BDNF molecules are functionally
equivalent to Met/Val BDNF proteins [9].
Genomic DNA was isolated from blood leukocytes using a
Nucleon BACC2 kit according to the manufacturer’s protocol (GE
Healthcare Life Science). Quality and quantity of genomic DNA
were determined spectrophotometrically using the absorbance
reading at 260 and 280 nm. Some DNA samples were repurified
by incorporating an additional phenol/chloroform (24:1 v/v)
extraction before recovery by ethanol precipitation. DNA
concentrations were measured using a NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies). The completion
rate of each assay was .99%, with an error rate of ,1%.
Val66Met BDNF genotypes at rs6265 were determined using a 59-
exonuclease allelic discrimination (TaqMan) assay using Reference
SNP ID: rs6265 (ABI Assay on Demand C_11592758_10; Applied
Biosystems), on an ABI7900 instrument. Genotyping error rate for
this assay was determined by replicate genotyping of samples and
was ,0.005.
Participants were also genotyped for the catechol-O-methyl-
transferase (COMT) Val158Met polymorphism (GenBank acces-
sion no. Z26491) that has also been associated with the modulation
of executive functioning [34,35]. A 59 nuclease assay using
fluorogenic detection probes was performed based on the G1947A
single nucleotide polymorphism within exon 4 of theCOMTgene
(NCBI nucleotide accession number Z26491), corresponding to
codon 158 of the COMT gene (NCBI accession number
BC011935). The detection oligonucleotide sequences were as
follows: 59-Fam6-CCTTGTCCTTCAcGCCAGCGA-TAMRA-
39 (Val158 detection probe) and 59-Vic-AC-
CTTGTCCTTCAtGCCAGCGAAAT-TAMRA-39 (Met158 de-
tection probe). FAM is 6-carboxyfluorescein, and TAMRA is 6-
carboxytetramethylrhodamine. The variant nucleotide in each
detection probe is shown in lowercase. The oligonucleotide
primers used for amplification were 59-TCGAGATCAACCCC-
GACTGT-39 (forward) and 59-AACGGGTCAGGCATGCA-39
(reverse). Target DNA amplification, fluorescence measurements,
and allele discrimination were accomplished using a ABI 7900
Sequence Detection System (Applied Biosystems).
Lesion Analysis
CT data were acquired during the Phase 3 testing period. Axial
CT scans without contrast were acquired at Bethesda Naval
Hospital on a GE Medical Systems Light Speed Plus CT scanner
in helical mode (150 slices per subject, field of view covering head
only). Images were reconstructed with an in-plane voxel size of
0.460.4 mm, overlapping slice thickness of 2.5 mm, and a 1 mm
slice interval. Lesion location and volume were determined from
CT images using the Analysis of Brain Lesion software [36,37]
contained in MEDx v3.44 (Medical Numerics) with enhancements
to support the Automated Anatomical Labeling atlas [38]. Lesion
volume was calculated by manual tracing of the lesion in all
relevant slices of the CT image then summing the traced areas and
multiplying by slice thickness. A trained neuropsychiatrist
performed the manual tracing, which was then reviewed by an
observer who was blind to the results of the neuropsychological
testing. As part of this process, the CT image of each subject’s
brain was spatially normalized to a CT template brain image. This
template was created by spatial normalization of a neurologically
healthy individual’s CT brain scan to MNI space using the
Preservation of General Intelligence following TBI
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Automated Image Registration program [39]. Lesion overlap
maps for patients with the Val/Val or Val/Met genotypes are
illustrated in Figures 1 and 2, respectively. Demographic and
background data for the Val/Val and Val/Met patient groups are
reported in Table S1 (see also [29–32]). No effects on test
performance were observed in these patient groups on the basis of
demographic variables (e.g., age, sex, ethnicity, years of education,
and lesion size; see also [28]). A direct comparison of brain regions
damaged in the Val/Val versus Val/Met genotypes is illustrated in
Figure 3. The profile of brain damage among these patient groups
primarily reflects common PFC subregions (highlighted in green)
and entails the majority of damaged voxels (Val/Val = 62.02%
shared with Val/Met; Val/Met= 76.33% shared with Val/Val).
An additional analysis performed on a subset of the Val/Val
patients whose lesion maps had maximal overlap with the full Val/
Met patient group (84.94%) is reported in Table S3 and Figs. S1–
S3, and replicates the findings of this study.
Neuropsychological Tests
We administered the Wechsler Adult Intelligence Scale, 3rd
Edition (WAIS; [40]) to investigate the neural substrates of key
competencies for general intelligence.
Wechsler Adult Intelligence Scale, 3rd Edition
The WAIS-III comprises 14 subtests grouped in four first-order
factors: verbal comprehension, perceptual organization, working
memory, and processing speed. In addition, a higher-order factor
representing general cognitive ability (g) is obtained from the
variance shared by the first-order factors. Table S2 provides a brief
description of each subtest (for further details concerning their
standardization, reliability, and validity, see [40]).
Confirmatory Factor Analysis
The following measurement model was tested (Fig. 4): (1) verbal
comprehension/crystalized intelligence (VC) was assessed by
vocabulary, information, similarities, and comprehension subtests;
(2) perceptual organization/fluid intelligence (PO) was as assessed
by matrix reasoning, block design, object assembly, picture
arrangement, and picture completion subtests; (3) working
memory (WM) was measured by arithmetic, digit span, and
letter-number sequencing subtests; (4) processing speed (PS) was
measured by digit symbol coding and symbol search subtests, (5)
the higher-order factor representing general intelligence (g)
predicts the above first-order factors.
This measurement model was tested for the 171 patients using
the AMOS program [41]. Fit indexes were reasonable: x2 = 150.3,
degrees of freedom (DF) = 73, x2/DF=2.1, RMSEA=0.079,
CFI= 0.94. All the coefficients in the model were statistically
significant (p,0.01). Perceptual organization/fluid intelligence was
the first-order factor best predicted by the higher-order factor
(0.83). Nevertheless, the remaining first-order factors were also
largely predicted by g (regression weights from 0.73 to 0.77).
Latent scores were obtained from this measurement model
using the AMOS imputation algorithm. These latent scores
estimate the true (error free) ability levels measured by the WAIS-
III. Therefore, specific variance associated with each subtests is
removed. The resulting five scores (general intelligence, fluid
intelligence, crystallized intelligence, working memory, and
processing speed) were submitted to voxel-based lesion-symptom
mapping analysis.
Results
Firstly, we computed scores on general cognitive ability as
obtained from the Armed Forces Qualitication Test (AFQT)
before TBI for Val/Val (n=97) and Val/Met (n=59) genotypes.
A one-way ANOVA was computed and the average difference was
not statistically significant (F=0.364, p=0.43, effect size = 0.13).
Therefore, there were no average differences in general intelli-
gence between Val/Val and Val/Met genotypes before TBI.
Figure 1. Lesion mapping results for Val/Val genotype patients (n=97). In each axial slice, the right hemisphere is on the reader’s left.
doi:10.1371/journal.pone.0088733.g001
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Secondly, these two groups of participants were systematically
compared in the five latent scores described above. Remember
that WAIS-III scores were obtained after TBI. Again, a one-way
ANOVA was computed. Now a substantial average difference is
observed between Val/Val and Val/Met genotypes across the five
latent scores (F=14.9, 6.4, 7.2, 14, and 16.9 for g, VC, PO, WM,
and PS respectively). As Figure 5 illustrates, this average difference
ranges from 6 to 8 IQ points (around half a standard deviation
Figure 2. Lesion mapping results for Val/Met genotype patients (n=59). In each axial slice, the right hemisphere is on the reader’s left.
doi:10.1371/journal.pone.0088733.g002
Figure 3. Lesion overlap map illustrating common and distinctive brain regions for Val/Val (blue) and Val/Met (yellow) genotype
patients. Overlap between Val/Val and Val/Met genotype patients is illustrated in green. In each axial slice, the right hemisphere is on the reader’s
left.
doi:10.1371/journal.pone.0088733.g003
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using the standard scale with a mean of 100 and a standard
deviation of 15). Values for the effect size (d) corresponding to
these average differences were: 0.68 for g, 0.42 for VC, 0.44 for
PO, 0.61 for WM, and 0.68 for PS. Therefore, while there was not
a difference in general cognitive ability between both genotypes
before TBI, a substantial and statistically significant average
difference was noted after TBI. Val/Met genotypes preserved their
cognitive ability, whereas Val/Val genotypes showed scores
notably decreased.
Discussion
The present study provides compelling evidence for a relation-
ship between variations in the Val66Met BDNF polymorphism
and preservation of general intelligence after penetrating TBI. In
previous studies, the Met allele had been found to be associated
with relatively impaired cognitive functions in healthy individuals
[11,13], stroke patients [42], psychiatric populations [43,44], and
in patients recovering from mild TBI [45]. However, in this study,
we demonstrated that the Met allele is protective for general
intelligence in patients with PFC damage after TBI. Met carriers
showed preservation of general intelligence compared with Val
carriers, across all facets of intelligence, including verbal compre-
hension, perceptual organization, working memory, and process-
ing speed.
We investigated the relative contribution of the Met allele to the
preservation of general intelligence in the presence of other factors
such as age, pre-injury cognitive performance, and volume brain
loss. Pre-injury cognitive performance on the Armed Forces
Qualification Task (AFQT) was not different for Met or Val
carriers. However, correlations between AFQT scores (before
TBI) and WAIS-III scores were generally lower for Val carriers,
except for verbal comprehension. This finding indicates that
AFQT scores are better predictors of intelligence after TBI for the
Met carries than for the Val carriers. The correlation values
(AFQT and WAIS-III factors) were (Met/Val carriers): g (0.76/
0.57), verbal comprehension (0.65/0.64), perceptual organization
(0.77/0.64), working memory (0.70/0.56), and processing speed
(0.61/0.42). Moreover, the profile of brain damage for the Met
and Val carriers was comparable and did not significantly differ in
terms of total percent volume loss (see Figs. 1–3).
The present study motivates new approaches to understanding
the molecular mechanisms underlying the association of the
Val66Met BDNF gene and preservation of general intelligence
after TBI. Prior research indicates that TBI is associated with an
early up regulation of BDNF in both animal models of
experimental brain injury [46] and in individuals with severe
TBI [47]. BDNF is synthesized in the brain as a propolypeptide,
which can be processed either intracellularly or extracellularly by
intracellular cleavage to mature BDNF followed by secretion,
secretion followed by extracellular cleavage to mature BDNF, or
secretion without subsequent cleavage [48]. Because proneuro-
trophins are important for proper folding, dimerization, and
targeting of the mature neurotrophins, substituting Met for Val in
Figure 4. Summary of structural equation modeling results (n=171).
doi:10.1371/journal.pone.0088733.g004
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proBDNF results in defective intracellular protein trafficking,
packaging, and regulated secretion [9,11].
ProBDNF and mature BDNF have two distinct receptors and
signaling cascades resulting in opposing effects on the nervous
system [48]. Whereas mature BDNF binds with high affinity to the
TrK B receptor tyrosine kinases (TrkB) and insures cell survival
[49], proBDNF binds with high affinity to the multifunctional p75
neurotrophin receptor (p75NTR) and triggers apoptosis [50,51].
Importantly, proneurotrophins are upregulated in pathological
conditions such as brain injury [48]. Particularly, proBDNF is
secreted by neurons and glial cells [9,51], when cell death prevails
after brain trauma [52,53]. After injury, p75NTR and many
binding partners are dynamically regulated and produce unique,
multimeric receptor complexes. One such binding partner is
sortilin, which specifically binds the prodomain of BDNF and
serves as a coreceptor with p75NTR in mediating cell death [54].
For example, when the interaction between proBDNF and
sortilin/p75NTR was blocked by sortilin (a protein that is a
member of the recently discovered family of Vps10p-domain
receptors) antagonists, the apoptotic actions of proBDNF on
cultured sympathetic neurons were abolished [51]. Moreover,
lesioned corticospinal neurons with lower sortilin expression were
more likely to survive the injury [55]. By extension, the reduced
secretion of proBDNF Met because of impaired intracellular
trafficking represents a plausible molecular model for protecting
individuals with the Met allele, especially in situations when a
substantial subpopulation of neurons is undergoing cell death as
may occur in TBI (see also [9]). Future molecular and cellular
studies on the regulation of proBDNF secretion after neuronal
injury will be required to verify this proposed molecular
mechanism.
Other recent research supports our observation for cognitive
preservation by carriers of the Met allele. A recent study in healthy
individuals revealed a positive effect of the Met allele for a
cognitive control function, namely response inhibition [17].
Furthermore, the presence of the Met allele was associated with
reduced cognitive decline in patients with multiple sclerosis [56] or
systemic lupus erythematosus [57]. In addition, accumulating
evidence in human lesion patients on the Val66Met BDNF
polymorphism and cognitive function indicates that the Met allele
exerts a protective effect for executive function [1] and cognitive
performance following TBI [28]. Finally, recent meta-analyses of
population-based case control studies on the Val66Met BDNF
polymorphism and mental disorders revealed that the Met allele
exerts a protective effect for substance-related disorders [26] and
results in decreased neuroticism as a vulnerability trait for anxiety
[27]. Thus, the weight of evidence suggests that the functional
effect of the Met allele may vary between cognitive functions and
brain regions under normal and pathological conditions. Recent
findings further indicate that the Val66Met BDNF polymorphism
does not capture all of the functionally important genetic variation
in cognitive performance following TBI and emphasize the
importance of investigating additional BDNF SNPs [45].
There are a number of limitations of the current study. First, in
any investigation attempting to link a gene with a discrete change
in cognitive function or pathology, it is often unclear how different
genotypes lead to altered phenotypes. Instead of an identified
genetic variant having a direct effect on executive function, it is
plausible that the genetic variation mediates its effect(s) through a
downstream functional change or through the regulation of some
other gene. Thus, future genotyping studies are necessary to
explore whether the preservation process may be mediated by
other candidate genes such as those from the neurotrophic factor
Figure 5. Wechsler Adult Intelligence Scale latent scores. g = general intelligence, VC = verbal comprehension, PO = perceptual organization,
WM = working memory, PS = processing speed, * = p,0.05, ** = p,0.01.
doi:10.1371/journal.pone.0088733.g005
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and TrK receptor families (see also [45]). Second, given that our
performance measures were determined 30 years after TBI in
participants generally in their late 50s, a number of long-term
changes in BDNF expression, directly, or indirectly, could
potentially impact executive function. For example, neuroprotec-
tive gene expression is altered in the elderly: TrkB mRNA levels
are reduced markedly in all portions of cortex [58]. In addition,
although changes in brain levels of apoptotic genes such as
p75NTR remain unchanged through adulthood, sortilin levels
increase with age, suggesting a mechanism that could shift the
balance to neurodegeneration with increasing age [59]. In the
future, longitudinal studies starting shortly after a TBI are needed
to explore the long-term molecular and cellular basis of the
Val66Met BDNF polymorphisms on potential recovery of
executive function and other cognitive domains. Finally, although
the Val/Val and Val/Met genotype groups in the present study
entail a similar profile of brain damage (Fig. 3; highlighted in
green) and the findings replicate when a subset of patients with
maximal lesion overlap in the Val/Val and Val/Met genotype
groups are compared (Table S3 and Fig. S1–S3), it remains
possible that subtle differences in the location of cortical damage
across these patient groups contribute to the observed differences
in general intelligence following TBI (Fig. 3 and Fig. S2; regions
highlighted in blue and yellow, respectively).
In conclusion, our findings provide novel evidence for a
relationship between the Met allele and the preservation of
general intelligence after penetrating TBI, supporting a protective
effect for specific competencies of psychometric g, including verbal
comprehension, perceptual organization, working memory, and
processing speed. For current clinical application, earlier triage
and extended cognitive rehabilitation is recommended for carriers
of the Val/Val allele to facilitate the best possible long-term social
and vocational outcomes for patients with PFC damage after TBI.
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Figure S1 Lesion mapping results for Val/Val focal
genotype patients (n=59). In each axial slice, the right
hemisphere is on the reader’s left.
(TIFF)
Figure S2 Lesion overlap map illustrating common and
distinctive brain regions for Val/Val Focal (blue) and
Val/Met (yellow) genotype patients. Overlap between Val/
Val Focal and Val/Met genotype patients is illustrated in green. In
each axial slice, the right hemisphere is on the reader’s left.
(TIFF)
Figure S3 Mean performance for Wechsler Adult Intel-
ligence Scale latent scores for a subset of 59 Val/Val
patients that share 84.98% of its voxels with the full Val/
Met patient group. g = general intelligence, VC= verbal
comprehension, PO=perceptual organization, WM=working
memory, PS= processing speed.
(TIFF)
Table S1 Demographic and background data. Note:
‘‘Age’’ refers to age at the time of Phase 3 evaluation. ‘‘Ethnicity’’
refers to the percentage of Caucasian veterans. ‘‘Sex’’ refers to the
percentage of male veterans. ‘‘Years of education’’ refers to the
total number of years of education the veterans completed. ‘‘Total
percent volume loss’’ refers to the total percent volume loss due to
brain damage in cm3.
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Table S2 Description of intelligence measures of the
WAIS.
(TIFF)
Table S3 Mean performance with effect sizes for
Wechsler Adult Intelligence Scale latent scores on a
subset of 59 Val/Val patients that share 84.98% of its
voxels with the full Val/Met patient group. g = general
intelligence, VC= verbal comprehension, PO=perceptual orga-
nization, WM=working memory, PS= processing speed.
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